KYAN Technologies

March 03, 2026
Diagnostics
KYAN Technologies is a functional precision medicine platform company dedicated to revolutionizing cancer care through our platform Optim.AI. This powerful tool empowers oncologists by providing them with critical insights to make informed clinical decisions for their patients. Optim.AI integrates small data AI and biological experiments to offer an efficient solution that transforms the identification of optimal outcomes from vast drug-dose combinations, revolutionizing the development and delivery of therapies to patients. In addition to our clinical test, KYAN is committed to conducting extensive research studies across various cancer indications to not only contribute to the advancement of biopharma services but also aid in the development of novel biopharmaceutical assets.

What is your next catalyst (value inflection) update?

We have successfully launched Optim.AI in Asia. Next value inflection is the launch of our clinical test and expanding our patient customer base in the US through Mayo and other US partners.

Year Founded

2022

Lead Product in Development

Optim.AI

Development Phase of Lead Product

Multiple Products in Market

Number of Unlicensed Products Looking for Licensing

1

CEO/Top Company Official

Hugo Saavedra

When you expect your next catalyst update?

June, 2026